This move is archived. Current quotes and coverage live on the stock page.
Follow CRDL
Cardiol Therapeutics Inc Class A (CRDL.TO) is having a good trading day, with shares up 3.47%.
In the latest trading session, Cardiol's stock price increased to CA$1.49. This rise shows investor optimism, likely driven by recent news about the company's clinical trials and financing activities.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$161.61M
52W high
$3.23
52W low
$1.23
1W change
-14.29%
Beta
0.66
Analyst Price Targets
Based on analyst covering CRDL · as of Oct 12, 2026
Wall Street analysts forecast CRDL stock price to rise 655.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.00
+655.5% Upside
Previously C$6.00 on Sep 17, 2026
Current Price
C$0.93
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
55.0%
Annualized
90-Day Vol
70.2%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.11
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.25 | C$1.04 – C$1.51 |
| 60 trading days | C$1.18 | C$0.90 – C$1.54 |
| 90 trading days | C$1.11 | C$0.80 – C$1.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Cardiol's recent financing and ongoing clinical trials, as these could be key drivers for future growth.
Stock rises 3.47% in a single day.
Cardiol Therapeutics' market cap is now CA$168.3 million, reflecting growing interest as the company moves forward with its clinical initiatives.
Bull case
The recent completion of a US$11.4 million financing round to support the MAVERIC Phase III trial puts Cardiol Therapeutics in a strong position for potential breakthroughs in heart disease treatment. Success in this area could greatly improve its standing in the market.
Bear case
However, despite the positive stock movement, the company still faces challenges. Its lack of profitability and dependence on external financing could be risky if the clinical trials don’t produce the expected results.
Recent Developments Fueling Growth
Cardiol Therapeutics recently wrapped up a US$11.4 million financing round, which is expected to extend its cash runway and support the MAVERIC Phase III trial. This trial is essential for developing new heart disease treatments, and positive results could significantly boost its stock performance.
Market Response and Future Outlook
The market's reaction to Cardiol's stock increase shows investor confidence in its strategic direction. As the company moves through its clinical trials, stakeholders will be watching closely. The outcomes could either strengthen or challenge its current valuation. Investors should stay alert for further announcements about trial results and the company’s financial health.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
